Biopreservation Market Poised to Witness a Significant Growth by 2023

 Market Scenario

The global biopreservation market size is expected to grow during the forecast period (2018–2023) at a CAGR ~11.2%.

Biopreservation is a use of natural flora and its antibacterial products to preserve biological material. Biopreservation is playing an important role in healthcare and food industry to preserve the biological material or food product for a long time. The increasing expenditure on healthcare, growing demand for stem cell preservation and awareness about its use with regards to treatment of diseases are expected to drive the growth of the market. Moreover, increasing awareness about personalized medicines and its applications are contributing to the growth of the market. According to the US Food and Drug Administration (FDA), The department has approved 16 personalized medicines in the year 2017, which accounts for 20% of total drug approvals.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6407

The rising high price of biopreservation instruments and its maintenance, stability issues related to the specimen and lack of skilled personnel for handling the biopreservation process may hamper the growth of the market during the assessment period.

Segmentation

The global biopreservation market has been segmented on the basis of product, biospecimen, and application.

On the basis of product, the market has been classified as media and equipment. The media subsegment has been further divided into nutrient media, sera, and growth factors and supplements. The equipment segment has been further divided into temperature control systems, accessories, alarms & monitoring systems, incubators, centrifuges, and other equipment. The temperature control systems segment has been further classified as freezers, cryogenic storage systems, thawing equipment, and refrigerators. The biospecimen segment has been divided into human tissue samples, organs, stem cells, and other biospecimens.

The market, by source, has been segmented into regenerative medicine, biobanking, and drug discovery. On basis of regenerative medicine, the market has been divided into cell therapy, gene therapy, and others. Biobanking segment includes human egg, human sperm, and veterinary IVF.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The biopreservation market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European biopreservation market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The biopreservation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The biopreservation market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

The Americas are likely to dominate the global biopreservation market owing to the adoption of advanced technology, increasing spending on healthcare R&D, the presence of a well-established healthcare system, and increasing in-house sample storage in hospitals and research institutes. Moreover, presence and recent merger and acquisition activities by market players in the region are contributing to the growth of the market.  For instance, in 2017, Cesca Therapeutics Inc. has acquired Sacramento’s SynGen Inc. for USD 1 million with this acquisition company has managed to add cell separation and cord blood processing products in their portfolio.

The European market is expected to be the second-largest biopreservation market. The market growth in this region can be attributed to the increasing number of births and with-it continuous increase in demand for umbilical cord preservation. According to the European Commission, in the year 2016 more than 5.1 million babies were born in Europe.  Moreover, a growing number of sperm and egg banks is contributing to the growth of the market in this region.

Asia-Pacific is expected to be the fastest-growing biopreservation market during the forecast period owing to the increasing population in the region, increasing awareness about stem cell preservation and continuous development in the healthcare sector due to government funding.

The market in the Middle East & Africa is expected to account for the smallest share of the global biopreservation market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Key Players

Some of the key players in the global biopreservation market are Thermo Fisher Scientific, Inc, VWR International, LLC., CUSTOM BIOGENIC SYSTEMS., BioLifeSolutions Inc., BioCision., Sigma-Aldrich Co., QIAGEN, Lifeline Scientific, Cesca Therapeutics Inc., Core Dynamics, Ltd., Princeton CryoTech, Biomatrica, Inc., Panasonic Biomedical,  Inc., Chart Industries, and ATLANTA BIOLOGICALS

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/biopreservation-market-6407

Hemangioblastoma Market Estimated to Witness a Staggering Growth by 2023

 Market Scenario

The global hemangioblastoma market is expected to grow at the rate of 6.1% during the forecast period (2018–2023)

Hemangioblastoma is a type of brain tumor, it is rare and slow growing disease. Uncontrolled growth occurs in the cell linings of blood vessels and it leads to a tumor. The disease-causing factor is unknown, but it is more likely to affect people with von Hippel-Lindau disease history or it can be sporadically. The growing awareness about cancer, increasing number of tumor surgeries, growing demand for advanced therapies and increasing healthcare expenditure are expected to drive the growth of the market. According to National Center for Biotechnology Information, US National Library of Medicine, 80% cases of hemangioblastoma are sporadic, whereas 20 to 25% develop in the context of Von Hippel–Lindau disease and it accounts for 7 to 10% of total brain tumor cases.

The rising cost of tumor treatment and scarcity of experts may hamper the growth of the market during the assessment period.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6404

Segmentation

The global hemangioblastoma market has been segmented on the basis of tumor site, diagnosis, and treatment.

On the basis of tumor site, the market has been classified as brain tumor, spinal cord tumor, and retinal tumor. The diagnosis segment has been classified as CT scan, MRI scan, and angiogram.

The market, by treatment, has been segmented into surgery, chemotherapy, radiotherapy, corticosteroids, and anticonvulsants. Radiotherapy segment has been classified into Conformal radiotherapy, Intensity-modulated radiotherapy (IMRT), Stereotactic radiotherapy and radiosurgery. Corticosteroid segment has been further divided into hydrocortisone, dexamethasone, methylprednisolone, and prednisolone. anticonvulsants segment has been further divided into carbamazepine, lamotrigine, levetiracetam, phenytoin, and sodium valproate.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The hemangioblastoma market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European hemangioblastoma market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The hemangioblastoma market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The hemangioblastoma market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

The Americas are likely to dominate the global hemangioblastoma market owing to the adoption of highly advanced technology, the presence of a well-established healthcare system, rising prevalence of cancer, and increasing healthcare expenditure. According to the National cancer institute, in 2016, 15.5 million cancer cases were found in united states, and it is expected to reach 20.3 million by 2016. Also, the expenditure on cancer care in 2017 was 147.3 billion.

The European market is expected to be the second-largest hemangioblastoma market share. The market growth in this region can be attributed to government funding and support of the healthcare sector and increasing cancer cases in the region. According to the European Commission, in 2016, The European nations (EU28), total expenditure of general governments on ‘healthcare’ amounted to 7.1 % of GDP and it was around USD1000 billion.

Asia-Pacific is expected to be the fastest-growing hemangioblastoma market during the forecast period owing to the increasing prevalence of chronic diseases, government support, rising investments in healthcare and presence of huge population. According to the World Economic Forum, in 2017, more than 55% of deaths occurred due to chronic and non-communicable diseases, which is more than 8 million and out of this one-third, people were below 60years.

The market in the Middle East & Africa is expected to account for the smallest share of the global hemangioblastoma market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Key Players

Some of the key players in the global hemangioblastoma market are Eli Lilly and Company, Bedford Laboratories, Astellas US Holding, Inc., DNAtrix, Inc., Advantagene, Inc., Burzynski Research Institute, Inc., Direct Therapeutics, Inc., Cellectar Biosciences, Inc., and others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/hemangioblastoma-market-6404

Global Tenecteplase Drug Market Racing to a Heightened Growth by 2023

 Tenecteplase drug is a recombinant enzyme used as a blood thinning agent. It is also called as clot buster, it dissolves the blood clots or clumps so that the blood could flow normally. Tenecteplase drug is mostly used to treat patients having heart-related diseases. Key factors, that favors the growth of this market are an increase in the rate of hypertension patient, increasing number of deep vein thrombosis cases, early aging and sitting for long period of time cause blood clotting. According to the American Heart Association 2017 report every 40 seconds, someone in the U.S has a heart attack. American College of Cardiology 2018 report states the death rate related to high blood pressure (BP) from 2005- 2015, has increased by 10.5%.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6401

 Further, the report presented statistics like- Coronary heart disease (CHD) (43.8%) is the major cause of deaths attributable to cardiovascular disease (CVD) in the US, followed by stroke (16.8%), high BP (9.4%), heart failure (HF) (9.0%), and other CVDs (17.9%). Further, they projected by 2035, more than 130 million adults in the US population (45.1%) to have some form of CVD. The total costs of CVD are expected to reach USD 1.1 trillion in 2035. Stroke prevalence in adults is 2.7% in the United States. Similarly, as per CDC’s facts and statistics about stroke in the United States report 2017, every 140,000 Americans die every year due to stroke. Thus, the increasing rate of cardiovascular diseases increases the market growth of tenecteplase drug market in this region.

Key players

Some of the key players in the global tenecteplase drug market companies are Boehringer Ingelheim International GmbH, Genentec Inc., Gennova pharmaceutical, Rewine pharmaceuticals, Hisun USA, Emcure Pharmaceutical, Merck Ltd. and Crunchbase Inc., and others.

Segmentation

The global tenecteplase drug market is segmented on the basis of application, dosage and end users.

The tenecteplase drug market, by application segmented into myocardial infarction, stroke, deep vein thrombosis. The tenecteplase drug market, by dosage intravenous dosage and intracatheter instillation dosage. Intravenous dosage is sub-segmented into adult and geriatric and intracatheter instillation dosage is sub-segmented into adult, children, and adolescents weighing 30 kg, infants. On the bases of end-user, it is segmented into hospitals and clinics, surgical centers, research centers and other.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/tenecteplase-drug-market-6401

Vitamin test Market Foreseen to Draw a Promising Growth by 2023

 Market Highlights

The Vitamin test market growth is expected to witness tremendous boost owing to the rising prevalence of vitamin deficiency. Other key factors such as the change to sedentary lifestyle, increase in smoking, and increasing consumption of junk food and packaged food, growing geriatric population, rising consumer awareness for vitamin benefits, and technologically advanced laboratories are contributing towards the growth of the market.  However, factors such as, high cost of vitamin test, limitations of the tests like false positives and false negatives and lack of awareness in developing countries are expected to restrict the market growth during the forecast period.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6377

Segmentation

The global Vitamin test market is segmented on the basis of type, technology, and end-user. the vitamin test market, by type, is categorized into vitamin B12 & folic acid test,folic acid (folate) test , carotene (beta carotene) test, vitamin K1 test, vitamin E test, vitamin d 25-dihydroxy (calcitriol) test, vitamin C test, vitamin B12 test, vitamin B6 test, vitamin B5 test, vitamin B3 (niacin) test, vitamin B2 (riboflavin) test, vitamin a (retinol) test, vitamin B1 test. On the basis of Technology, the market is segmented into high-performance liquid chromatography (HPLC), radioimmunoassay, ELISA tests, chemiluminescent immunoassay (CLIA)and liquid chromatography-tandem mass spectrometry. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, research centers, and others.

Regional Analysis

The Americas is the largest in the market owing to the increasing prevalence of vitamin deficiency and growing healthcare expenditure. According to the The United States Department of Agriculture in 2014, 50% of Americans are deficient in vitamin A, vitamin C, and magnesium. Such a high incidence of vitamin deficiency drives market growth in this region.

Europe (UK, Belgium, France, and Netherlands) is the second largest vitamin test market during the forecast period. The increasing in awareness for vitamins and vitamin testing drives the market in this region. The European Laboratory of Nutrients (ELN) is an advanced laboratory for testing the nutrient levels in European population. Every year European Laboratory of Nutrients (ELN) organizes an international symposium titled ‘Advanced Clinical Nutrition – Nutrients for Prevention and Cure of Disease’. Thus enhancing vitamin testing market in this region.

Asia-Pacific was projected to be the fastest growing region for the global vitamin test market in 2017. The market is expected to witness growth owing to the rising prevalence of chronic diseases in this region. Also, the presence of technologically advanced countries like China and Japan in this region is expected to influence the market growth in this region.

The Middle East and Africa accounts for the least share due to low per capita income and lack of availability of well-trained healthcare professionals. However, the rising healthcare services both at the hospital level and in the community are expected to influence the market in a positive way.

Key Players

Some of the key players in the global Vitamin test market are VitaMe Technologies Inc., R-Biopharm AG, Abbott Laboratories, ImmunoDiagnostics Inc., F. Hoffman-La Roche, Siemens AG, Diazyme Laboratories, DiaSorin S.p.A, ORGENTEC Diagnostika GmbH and others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/vitamin-test-market-6377

Healthcare Claims Management Market Foreseen to Draw a Promising Growth by 2023

 Market Scenario

Global healthcare claims management market is expected to grow significantly over the forecast period. It is estimated that the global healthcare claims processing market is expected to register a CAGR ~ 5.37% during the forecast period of 2018–2023. Healthcare claims management process comprises of various tasks such as organization, billing, filling, updating, and processing of medical claims related to the diagnosis, treatment, and medication of patients.

The global market is driven by factors such as increase in ageing population, rise in incidence of chronic diseases, improved focus on healthcare quality services and advent of innovative treatments & technologies.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6376

Factors such as increasing concerns regarding the patient data safety and security limit and data breaches and loss of confidentiality, lack of skilled IT professionals in healthcare are restraining the growth of medical claims management solutions market. According to the National Health Insurer Report Card published in 2011 by American Medical Association (AMA), around $17 billion a year (on an average) could be saved by eliminating errors in claims.

Segmentation

The global healthcare claims management market has been segmented into component, delivery mode type and end-user. The market, based on component, has been segmented into software and services. The market, by delivery mode, has been segmented into on-premise and cloud based. The market, by type, has been segmented into integrated and standalone. The market, by end-user has been segmented into healthcare payers and providers.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The healthcare claims management market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European healthcare claims management market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The healthcare claims management market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The healthcare claims management market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players

Cerner Corporation (US), McKesson Corporation (US), Athenahealth (US), eClinicalWorks (US), Optum, Inc. (US), Conifer Health Solutions (US), nThrive (US), Avaya Inc. (USA), Oracle Corporation (US), Infor Inc. (US), Allscripts Healthcare Solutions, Inc. (US), Accenture plc. (Ireland), IBM Corporation (US), Cognizant Technology Solutions Corporation (US) and Genpact Limited (US) are some of the key players in the global healthcare claims management market.

Regional Market Summary

Geographically, the Americas is expected to dominate the global healthcare claims management market due to the growing HCIT investments in the region and the presence of regulatory mandates favouring the implementation of healthcare claims management solutions.

Europe is expected to hold the second largest position in the global healthcare claims management market. The market growth in this region is because of the rise in prevalence of chronic diseases, presence of well-established healthcare system and increase in insurance coverage.

Asia-Pacific is estimated to be the fastest growing region in the market due to the improved healthcare infrastructure and increasing geriatric population.

On the other hand, the Middle East & Africa has the least share of the market. This is due to low technological advancements in the field of healthcare IT.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/healthcare-claims-management-market-6376

Unilateral Vocal Cord Paralysis Market - Factors Driving Growth Post 2023

 Market Scenario

The global unilateral vocal cord paralysis market is expected to grow at the rate of 3.6% during the forecast period (2018–2023).

Vocal fold paralysis is neurogenic (arising from the nerves) voice disorder. it is of two types bilateral and unilateral vocal cord paralysis. Unilateral vocal cord paralysis is a condition where only one-fold shows no movement or very limited movement. Breathy voice, swallowing disability, weak cough and shortness of breath are some characteristics of unilateral vocal fold paralysis. The adoption of advanced technology, technological advancement, increasing healthcare expenditure, increasing prevalence of factors causing vocal cord/fold paralysis and increasing investment in healthcare are expected to drive the growth of the market. For instance, National Institute on Deafness and Other Communication Disorders (US) has recently provided a grant of USD 1.8 million for developing pliable, new vocal cord tissue to replace damaged tissue that can alter or silence a person’s voice.

The rising cost of treatment may hamper the growth of the market during the assessment period.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6356 

Segmentation

The global unilateral vocal cord paralysis market has been segmented on the basis of treatment, diagnosis, and end-user.

On the basis of treatment, the market has been classified into medical treatment and surgical treatment. The medical treatment segment has been further divided into medication and voice therapy. The voice therapy segment has been further divided into direct voice therapy, voice hygiene treatment, and voice test environment treatment. Direct voice therapy subsegment has been classified into flow phonation and resonant voice and respiratory support technique. Surgical treatment segment has been divided into endoscopic injection and permanent treatment. Permanent treatment segment has been further divided into vocal fold injection and laryngeal framework surgery.

The diagnosis segment has been divided into laryngoscopy and laryngeal electromyography (LEMG) and blood test & scans. Blood test and scans segment has been further classified into X-rays, CT scans, MRI scans.

The market, by end-user, has been segmented into hospitals, clinics, diagnostic centers, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The unilateral vocal cord paralysis market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European unilateral vocal cord paralysis market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The unilateral vocal cord paralysis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.

The unilateral vocal cord paralysis market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

The Americas are likely to dominate the global unilateral vocal cord paralysis market growing prevalence of voice disorders, the presence of a well-established healthcare sector, and increased expenditure for the healthcare sector. According to the National Institute on Deafness and other Communication Disorders (NIDCD) around 7.6% of the total adult population is suffering from speech-related problems.

The European market is expected to be the second-largest unilateral vocal cord paralysis market share. The market growth in this region can be attributed to the favorable reimbursement policies, advancement in technology and increasing healthcare expenditure due to high per capita income. According to an article published in 2016 by the World Health Organization (WHO), The European Nations (EU28) has spent 7.1 % of GDP on healthcare and it was around USD1000 billion.

Asia-Pacific is expected to show prominent growth during the forecast period owing to the government support and funding for healthcare, increasing prevalence of speech disorders, rising investments in healthcare, huge patient pool and increasing prevalence of head and neck injuries are anticipated to propel the market growth as these injuries can lead to vocal cord paralysis. According to the Indian Head Injury Foundation, India has the highest rate of head injuries in the world. It also stated that in India, more than 100,000 lives are lost every year with over 1 million suffering from serious head injuries.

The market in the Middle East & Africa is expected to hold the smallest share of the global unilateral vocal cord paralysis market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Key Players

Some of the key players in the global unilateral vocal cord paralysis market are Stryker Corporation, Hoya Corporation, Teleflex Incorporated, Therapy Solutions Inc., Smiths Group plc, Smart Speech Therapy LLC, Olympus Corporation of the Americas, Medtronic Plc., KARL STORZ SE & Co. KG, RENÚ, Cytophil, Inc., Acclarent, Inc.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/unilateral-vocal-cord-paralysis-market-6356

Next-Generation Sequencing Market - Factors Driving Growth Post 2025

 Market Highlights

There are various diseases that have their roots in genetics such as cancer, diabetes, Alzheimer’s, arthritis, heart disease, etc. To discover viable treatment for these diseases, researchers are looking to discern how genes work. The next-generation sequencing market has been gaining impetus due to the fact that next-generation sequencing is integral to the field of genomics. The NGS technologies are implemented for several applications, including whole-genome sequencing, de novo assembly sequencing, resequencing, and transcriptome sequencing at the DNA or RNA level. The successful application of next-generation sequencing can lead to predicting genes, protein-coding regions, and pathways.

Illumina, Helicos Biosciences, Thermo Fisher Scientific, Roche, Pacific Bioscience, ABI Life Technologies, and Oxford Nanopore are some of the companies that are implementing different NGS technologies which in turn will augment global next-generation sequencing market share is estimated to reach at a CAGR of 18.05% over the forecast period and USD 20,347.45 Million by 2025.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6354 

Segmentation

The Next Generation Sequencing Market has been classified by Technology, Service and Product, Application, and End-User.

By technology, the next-generation sequencing market has been segmented as whole-genome sequencing, methyl sequencing, whole-exome sequencing, targeted resequencing, CHIP sequencing, RNA sequencing, and de novo sequencing.

By service & product, the next-generation sequencing market has been segmented as consumables, sample preparation, sequencing services, and platforms and services for platforms.

By application, the NGS market has been segmented as genetic screening, drug discovery, diagnostics, agriculture and animal research, and others.

End-users segmentation of the next generation sequencing market includes academic institutes and research centers, pharmaceutical and biotechnology companies, hospitals and clinics, and other end-users.

Regional Analysis

Owing to the rising number of funds being granted for research into genomics and initiatives adopted by the government to rein in cases of genetically occurring diseases and demand to improve the healthcare sector is estimated to augment the growth of the next-generation sequencing market in North America. Increased competition among market players as well as acquisitions and mergers are expected to drive the growth of the market in the region.

The next-generation sequencing market in Europe is expected to hold the second-largest revenue share due to the presence of some of the leading next-generation sequencing technology companies and an educated population inclined on the advancement of next-generation sequencing technology. Though diverse regulations and a fragmented NGS market might restrain the growth of the market in the region, favorable funding scenario and immense support for scientific research would augment the next-generation sequencing market in the region.

The next-generation sequencing market share in Asia-Pacific is projected to witness expansion over the coming years due to growing demand for advanced technology and access to enhanced treatment facilities, better adoption of advanced genomics, an increase in disposable income, and rising investments in diverse treatment options by pharmaceutical companies.

Due to lack of technical knowledge, an underdeveloped healthcare sector, and poor medical facilities the next-generation sequencing market in the Middle East and Africa is expected to garner the smallest share.

Competitive Landscape

Some of the Key Players in the Global Next-Generation Sequencing Market Illumina, Inc., Thermo Fisher Scientific, Inc., Pacific Biosciences of California, Inc., BGI, PerkinElmer, Agilent Technologies, QIAGEN N. V., Macrogen Inc., Oxford Nanopore Technologies, Ltd., and Eurofins Scientific.

Industry News

Recently, Thermo Fisher Scientific launched its Ion Torrent Genexus System, the first fully integrated, next-generation sequencing platform that delivers results economically in a single day. This turnkey solution is designed to enable local hospitals to adopt NGS testing.

According to a study published in Clinical Lung Cancer local hospitals are severely challenged when it comes to providing NGS-based genomic testing at present even though hospitals are where most patients are treated. Due to limitations to NGS adoption, such as product complexity and cost, the vast majority of local molecular laboratories rely on single-gene tests. Some laboratories even have to outsource testing for more comprehensive NGS analysis as single-gene tests fail to provide a complete genomic profile of a tumor. Ion Torrent Genexus System is expected to solve many of the problems faced by hospitals when it comes to gene testing thus increasing growth scope for next-generation sequencing.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/next-generation-sequencing-market-6354